TransMedics Group (NASDAQ:TMDX) Coverage Initiated at Robert W. Baird

Equities research analysts at Robert W. Baird started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $200.00 price target on the stock. Robert W. Baird’s target price would suggest a potential upside of 34.88% from the stock’s current price.

Several other research analysts also recently commented on the company. Needham & Company LLC started coverage on TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Piper Sandler raised their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. TD Cowen raised their price objective on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Oppenheimer raised their price objective on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $174.30.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $148.28 on Tuesday. The stock has a 50 day moving average of $156.02 and a 200 day moving average of $130.77. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $177.37. The firm has a market cap of $4.95 billion, a PE ratio of -436.12 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period last year, the company earned ($0.03) EPS. On average, research analysts expect that TransMedics Group will post 1.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock worth $9,650,880 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in TMDX. Wasatch Advisors LP acquired a new stake in shares of TransMedics Group during the first quarter worth about $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new stake in TransMedics Group in the second quarter valued at about $39,862,000. Driehaus Capital Management LLC lifted its position in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares during the period. First Light Asset Management LLC lifted its position in TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the period. Finally, Hood River Capital Management LLC acquired a new stake in TransMedics Group in the second quarter valued at about $18,854,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.